Lupus & antiphospholipid syndrome
Efficacy and safety of telitacicept in the treatment of systemic lupus erythematosus: A retrospective real-world study
Authors' conclusion
In this real-world study, telitacicept combined with conventional therapy showed good onset efficacy and safety for treating SLE patients.
Study context
- Population
- Chinese systemic lupus erythematosus (SLE) patients treated with telitacicept, April 2021–March 2022
- Participants
- 41 patients
- Exposure
- Telitacicept, 24-week outcomes vs baseline
- Telitaciceptn = 41
- Outcome
- SLEDAI-2K score
- Follow-up
- 12 and 24 weeks
Methodological detailssingle-centre, observational, real-world
- Single-centre
- Observational
- Real-world
Main finding
As reported in the abstract
SLEDAI-2K at baseline, mean ± SD
10.0 ± 6.85
SLEDAI-2K at 12 weeks, mean ± SD (vs baseline p < .001)
6.25 ± 5.46
SLEDAI-2K at 24 weeks, mean ± SD (vs baseline p < .001)
4.18 ± 4.78
Observational data: associations, not effects.
Further findings
Organ involvement by SLEDAI-2K
- Proportion significantly decreased in skin/mucosa and musculoskeletal involvement
Mean GC dose (prednisone equivalent) · 12 and 24 weeks
- Baseline, mg/d
- 20.87 ± 16.71
- 12 weeks, mg/d (p < .001)
- 14.19 ± 8.88
- 24 weeks, mg/d (p = .001)
- 9.86 ± 4.25
C3 and C4 levels
- Increasing trend
24-h urinary protein in LN (subgroup) · 24 weeks
- Baseline, g/day
- 2.81 ± 3.83
- 24 weeks, g/day (p = .005)
- 1.00 ± 1.32
- Decline (IQR 35.61%, 76.30%)
- 68.66%
Albumin in LN (subgroup)
- Significantly improved (p = .003)
Safety
| Outcome | Values |
|---|---|
| TEAEsAll mild and moderate | Telitacicept 9 events · patients with TEAEs 6 |
Original publication
Efficacy and safety of telitacicept in the treatment of systemic lupus erythematosus: A retrospective real-world study. Lupus. Published 20 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →